Mesh Bio, MultiOmic Health to Generate AI-Driven Insights on Asian Metabolic Diseases

Mesh Bio, MultiOmic Health to Generate AI-Driven Insights on Asian Metabolic Diseases

Singaporean health tech startup Mesh Bio and UK-based drug discovery firm MultiOmic Health have started collaborating to build a huge multi-omics dataset that will provide insights into metabolic syndrome-related conditions among Asians. The large multi-omics dataset they are building will enable the companies to advance their respective R&D programmes to develop precision therapeutic and diagnostic products for patients with metabolic syndrome-related conditions. "Longitudinal multi-omics data combined with deep clinical phenotyping is essential to developing transformative therapeutics and diagnostics in chronic multi-factorial diseases," said Angeli Möller, vice-chairperson and co-founder of the global advocacy group Alliance for Artificial Intelligence in Healthcare.




Next Article

Did you find this useful?

Medigy Innovation Network

Connecting innovation decision makers to authoritative information, institutions, people and insights.

Medigy Logo

The latest News, Insights & Events

Medigy accurately delivers healthcare and technology information, news and insight from around the world.

The best products, services & solutions

Medigy surfaces the world's best crowdsourced health tech offerings with social interactions and peer reviews.


© 2024 Netspective Media LLC. All Rights Reserved.

Built on May 23, 2024 at 3:57am